<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409016</url>
  </required_header>
  <id_info>
    <org_study_id>17-1940.cc</org_study_id>
    <nct_id>NCT03409016</nct_id>
  </id_info>
  <brief_title>Biomarkers of Immune-Related Toxicity</brief_title>
  <official_title>Identifying Biomarkers of Immune-Related Toxicity in Cancer Patients Treated With Immune Checkpoint Inhibitors; A Pilot Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer League of Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, correlative pilot study evaluating potential biomarkers predictive&#xD;
      of immune-related adverse events associated with immune checkpoint inhibitor therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, correlative pilot study evaluating potential biomarkers predictive&#xD;
      of immune-related adverse events associated with immune checkpoint inhibitor therapy. The&#xD;
      study includes a control population of patients receiving standard chemotherapy as a&#xD;
      comparator. Patients will undergo blood draws at 4 time-points while on standard of care&#xD;
      treatment. There are no study-related medications or interventions beyond blood sampling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identifying biomarkers predictive of immune-related toxicity associated with immune checkpoint inhibitor therapy.</measure>
    <time_frame>30 Months</time_frame>
    <description>Difference in baseline inflammatory/autoimmune marker(s) in patients developing immune-related adverse events on immune checkpoint inhibitor therapy according to CTCAE v 4.0 versus those who do not</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory/autoimmune markers.</measure>
    <time_frame>6 Months</time_frame>
    <description>To evaluate the change in inflammatory/autoimmune markers prior to and at 3 time points on immune checkpoint inhibitor therapy, with comparison to patients treated with standard chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory/autoimmune markers</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the impact of change in these markers on patient reported adverse events using the PRO-CTCAE</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Immune Checkpoint Inhibitor Therapy</arm_group_label>
    <description>Patients starting treatment with ipilimumab, nivolumab, pembrolizumab, or atezolizumab, alone or in combination, for treatment of a metastatic solid tumor cancer will be enrolled. Patients will receive checkpoint inhibitor therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>An additional 18 patients starting standard chemotherapy will be enrolled as a control population. Patients will receive chemotherapy per standard protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Testing</intervention_name>
    <description>Patients will undergo therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Immune Checkpoint Inhibitor Therapy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        These patients will be enrolled only at the University of Colorado Cancer Center in the&#xD;
        outpatient clinic setting.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Metastatic solid tumor cancer of any primary site, with the exception of lymphoma&#xD;
&#xD;
          2. â‰¥18 years of age&#xD;
&#xD;
          3. Life expectancy &gt;6 months&#xD;
&#xD;
          4. Starting new regimen of ipilimumab, nivolumab, pembrolizumab or atezolizumab as a&#xD;
             single agent or in combination according to standard of care or through compassionate&#xD;
             use granted by the pharmaceutical company (immune checkpoint inhibitor arm only) OR&#xD;
             Starting new regimen of standard cytotoxic chemotherapy (control arm only)&#xD;
&#xD;
          5. Provision to sign and date the consent form&#xD;
&#xD;
          6. Stated willingness to comply with all study procedures and be available for the&#xD;
             duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior immune checkpoint inhibitor therapy with anti-CTLA4, anti-PD1 or anti-PD-L1&#xD;
             targeting agent&#xD;
&#xD;
          2. Known autoimmune disease&#xD;
&#xD;
          3. Known acute or chronic infection, including viral infections such as Hepatitis B, C,&#xD;
             and HIV&#xD;
&#xD;
          4. Chronic treatment with immune suppressive medications, including steroids, at the time&#xD;
             of study enrollment&#xD;
&#xD;
          5. Concomitant treatment with a monoclonal antibody in addition to cytotoxic chemotherapy&#xD;
             (i.e. bevacizumab, cetuximab, trastuzumab) (control arm only)&#xD;
&#xD;
          6. Known pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah L Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Glass</last_name>
    <phone>720-848-0755</phone>
    <email>andrea.glass@cuanschutz.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Morrow</last_name>
      <phone>720-848-0665</phone>
      <email>mark.morrow@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah L Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 17, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune Checkpoint Inhibitors</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Immune Related Adverse Event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

